Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe today to attendees of the Bell Potter Healthcare Conference 2024.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address to be provided by Mr Neville Gardiner and the Investor Presentation to be provided by Dr Richard Lipscombe to shareholders.
Proteomics International Laboratories Ltd (ASX:PIQ) today announces the appointment of Aaron Brinkworth to its Board as independent, non-executive Director, in concert with the retirement of Roger Moore as non-executive Director.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to provide the following update on its business activities for the three months to 30 September 2024 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce the publication of groundbreaking results showing the PromarkerD predictive test can predict renal decline in type 1 diabetes.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce outstanding results for its world-first diagnostic blood test to identify esophageal adenocarcinoma, PromarkerEso.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees at the Pitt Street Research Life Sciences Conference, Sydney on 19 September 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce the appointment of James Williams to its Board as an independent nonexecutive director, effective 16 September 2024.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce groundbreaking results showing the PromarkerD predictive test can predict renal decline in type 1 diabetes.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to provide the following update on its business activities for the three months to 30 June 2024.
Notice of Annual General Meeting/Proxy Form
Issue of Equity Incentives to Employees
Interim Financial Report and Appendix 4D
Issue of Equity Incentives to Employees
